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Background: Research and practice indicate that a sizeable amount of prescribed drugs is
never used.
Aim: To assess the habitual up-take of medicines in subjects with respiratory symptoms/
diseases or impaired lung function in general population samples.
Methods: Data regard 4010 subjects (8–88 years) from the rural area of Po River Delta
(North Italy) and the urban area of Pisa (North-Central Italy). Analyses concern the
habitual use of any or specific medicines (broncho-pulmonary, anti-allergic, cardio-
vascular, diuretic) in subjects with asthma, chronic bronchitis/emphysema (COPD), COPD
or chronic cough/phlegm (COPDsx), and airways obstruction (AO, FEV1/FVCo70%).
Results: Asthma, COPD, COPDsx, and AO were present in 6%, 5%, 21%, and 13% of cases,
respectively. Only 37% and 21% of subjects with respiratory symptoms/diseases used any or
specific medicines, respectively. The subjects with COPD exhibited the highest prevalence
of assumption (59% for any drug, 38% for specific medicines), followed by asthmatics
(42% and 30%), and subjects with AO (40% and 25%). After accounting for sex, age,
residence area, smoking habit, education, and presence of comorbidity, the conditions
significantly related to any medicine up-take were COPD (OR 1.65, 95% CI 1.08–2.53) and
asthma (OR 1.47, 95% CI 1.01–2.12). Only asthma resulted significantly associated with the
use of specific drugs (OR 3.11, 95% CI 1.94–4.97). Drug use was higher in the urban than in
the rural area.Elsevier Ltd. All rights reserved.
502031; fax: +39 050503596.
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Respiratory health and medicine use in two Italian areas 83Conclusion: The results indicate that most people in the general population do not use
drugs, in spite of reported respiratory disorders. The underuse of medicines seems lower in
the urban area.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pharmacoepidemiology has increasingly become an impor-
tant discipline to assess patterns of medicine use in the
general population.1
Data on drug consumption can be obtained from different
sources: pharmacies, physician prescriptions, hospitals, and
self-reports by standardized questionnaires. Information
collected through practitioners’ prescriptions or through
hospitals’ administrations should be interpreted cautiously
because they may not correctly indicate the amount of drug
use. Although pharmacy records are reasonably complete,2
they might show no sufficient quality for pharmacoepide-
miological studies as concerns the actual use of medicine.
The frequency of different drugs’ use might be considered
as a proxy of the illness prevalence, but research and practice
indicate that a sizeable amount of prescribed drugs is never
used.3 This seems to be particularly evident for subjects with
respiratory diseases. An Italian study found that 26% of
asthmatics did not use specific drugs, and only 65% of the
subjects who had received the prescription of anti-asthmatic
medicines declared to have taken them.4 In Sweden, this
percentage is even lower (60%).5 The European Community
Respiratory Health Survey (ECRHS) found that 8–29% of
subjects with asthma-related symptoms made use of anti-
asthmatic drugs.6 A recent multicentre study performed in 29
centres of North America, Europe, and Asia, reports that the
use of preventive medications, even in patients with severe
persistent asthma, is low, ranging from 26% in Western Europe
to 9% in Japan.7 In addition, several studies show that the use
of specific medications appears to be unassociated with the
presence of the specific disease.8,9 Under-treatment of
diseases like asthma seems to be quite common.4,6
Self/interviewer-administered questionnaires may be more
suitable than pharmacy retails or doctors’ prescriptions to
supply better information on the actual use of medicines.10
A medicine intake should be assessed considering the
characteristics of the subjects, such as gender, age, smoking
habit, education level. Residence area is also relevant. A
different social context may influence the behaviour in both
prescribing and assuming medicines. The assessment should
be done not only in subjects living in different countries,6
but also in those living within a small geographical area,
where large differences in the prevalence of respiratory
symptoms can be found.11
The scientific literature reports significant associations of
non-respiratory diseases with chronic obstructive pulmonary
disease (COPD) and asthma.12–14 Thus, the presence of
comorbidity has to be considered, in order to correctly
evaluate drugs’ up-take in subjects with respiratory diseases.
The aim of this study was to assess the habitual use of
medicines by subjects with respiratory disorders living in
two different Italian areas, taking into account host and
environmental factor.Methods
Data were collected during the second cross-sectional
survey of two prospective studies on the natural history of
COPD and its risk factors, carried out in the rural area of the
Po Delta (near Venice, Northern Italy) from 1988 to 1991
(2841 subjects, age range 8–75 years), and in the urban area
of Pisa (Central-Northern Italy) from 1991 to 1993 (2841
subjects, age range 8–97 years). Both studies were
performed following the same standardized protocol on
general population samples, according to a random multi-
stage, stratified, cluster design. Details are described in
previous articles.15–19 The study protocol also included a
venous blood withdrawal for IgE determination and, for
consenting subjects, additional questions on medicine
consumption.
The analyses concern the subsample of subjects who
accepted to undergo the blood withdrawal (N ¼ 4010,
response rate 71%, 8–88 years) and for which, therefore,
we had information on the use of drugs. The subsample did
not significantly differ from the whole sample (N ¼ 5682) as
concern age, sex, residence, prevalence of respiratory
symptoms/diseases, and current comorbidities (Table 1). In
the subsample, there were higher prevalence rates of
current- and ex smokers and more educated subjects than
in the whole sample.
Information on sex, age, respiratory disease (RD),
comorbidity (non-respiratory disease ¼ NRD), smoking ha-
bit, and educational status, was collected through a
standardized interviewer-administered questionnaire, de-
veloped by the National Research Council (CNR), modified
version of the National Heart Lung and Blood Institute
(NHLBI) standard questionnaire.
As reported in our previous paper, we collected informa-
tion on habitual or occasional use of medicines.20 For these
analyses, we considered only the habitual up-take, accord-
ing to a positive answer to the question: ‘‘Are you habitually
assuming medicines?’’.
The results concern the use of both any and specific
(broncho-pulmonary, anti-allergic, cardio-vascular, and
diuretic) therapeutic groups, at the moment of the inter-
view. Medicines were classified into therapeutic groups,
defined by CODIFA (Pharmaceutical Informer, approved by
the Health Minister of Italy),21 according to Anatomical
Therapeutic Chemical (ATC) classification system. Only 1.6%
of subjects did not report the name of the drug for lack of
memory. Such completeness of information was achieved
after telephoning to those who had not answered the
question.
Considered RD were: (a) diagnosis of current asthma;
(b) diagnosis of chronic bronchitis/emphysema (COPD);
(c) COPD/chronic cough/chronic phlegm (COPDsx).
During the above reported epidemiological surveys,
spirometric tests were performed by the subjects p75
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Table 1 Comparison between the whole sample and the studied subsample.
Mean (S.D.) p By Mann–Whitney
Whole sample (N ¼ 5682) Subsample (N ¼ 4010)
Age 42.9 (17.1) 42.3 (17.1) NS
N (%) N (%) p By w2
Residence area
Po Delta 2841 (50.0) 1946 (48.5) NS
Pisa 2841 (50.0) 2064 (51.5) NS
Males 2630 (46.3) 1938 (48.3) NS
Education
Low 2635 (46.4) 1721 (42.9) o0.01y
Intermediate 1620 (28.5) 1181 (29.5) NSy
High 1419 (25.0) 1104 (27.5) o0.01y
Missing 8 (0.1) 4 (0.1)
Smoking habit
Current 1501 (26.4) 1141 (28.5) o0.05y
Ex 1520 (26.8) 1160 (28.9) o0.05y
RD
Asthma 359 (6.3) 244 (6.1) NS
COPD 286 (5.0) 189 (4.7) NS
COPDsx 1145 (20.2) 862 (21.5) NS
AOz 524 (12.0) 445 (12.9) NS
Current co-morbidity
Cardio-vascular 1735 (30.5) 1231 (30.7) NS
Gastro-duodenal/liver 491 (8.6) 342 (8.5) NS
Kidney/colon 1645 (29.0) 1142 (28.5) NS
Joint 2344 (41.3) 1653 (41.2) NS
Dermatological 391 (6.9) 321 (8.0) NS
RD: respiratory symptoms/diseases; COPD: confirmed diagnosis of chronic bronchitis and/or emphysema; COPDsx: COPD or chronic
cough/phlegm. AO: airways obstruction according to the GOLD criterion (FEV1/FVC o70%).
Difference between the whole sample and the studied subsample; NS: not significant.
yIndependent comparison of the proportions.
z4353 and 3438 subjects with valid lung function tests in the whole sample and subsample, respectively.
M. Simoni et al.84years, in order to obtain two comparable samples in the
same age range. In the studied subsample, acceptable lung
function tests, according to the protocol of the American
Thoracic Society (ATS),22 were available for 3438 subjects.
Lung function was determined by an automated pneumo-
tachograph (Pulmonary System 47804/S, Hewlett-Packard,
Waltham, MA) in Po Delta, and a water-sealed spirometer in
Pisa (Baires Biomedin, Padova, Italy). More details on lung
function protocol are in other papers.23,24 Airway Obstruc-
tion (AO) was considered according to the GOLD criterion25:
FEV1/FVC ratio less than 70%.
In the logistic regression models, NRD were hierarchically
classified in five independent categories: (1) cardio-vascular
diseases (heart diseases or hypertension or hypercholester-
olemia/lipidemia or diabetes); (2) gastro-duodenal/
liver diseases; (3) kidney/colon diseases; (4) joint diseases;
(5) dermatological diseases.
The subjects were defined as: non-smokers, if they had
never smoked any kind of tobacco regularly; smokers, if they
were currently smoking at least one cigarette daily (at themoment of the interview); ex smokers, if they had formerly
smoked regularly until 6 months or more before the
examination. Mean (S.D.) duration and range of smoking
were 22 years13 and 1–58 years for ex smokers, 28 years15
and 1–70 years for current smokers.
In Italy, the school system includes: elementary school
(5 years), junior high school (3 years), high school (5 years),
and university (3–6 years). Accordingly, educational status
was classified as ‘‘low’’ (none/elementary school), ‘‘inter-
mediate’’ (junior high school), and ‘‘high’’ (high school/
university).
Statistical analyses were carried out using the Statistical
Package for the Social Sciences (SPSS).26 We used the
following routines: frequency distributions, w2 test, Mann–
Whitney non-parametric test, logistic regression analysis
with the use of drugs as dependent variable (reference
category ¼ no use).
The study was approved by the Ethical Committee of the
University of Ferrara. Data were treated following the
requirements of the Italian law on Privacy & Confidentiality
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in the study did not occur until informed consent was
obtained.Results
General characteristics of the samples
Table 2 shows general characteristics of the samples.
Subjects living in the urban area of Pisa were significantly
older than those living in the rural area of the Po Delta.
Regarding gender and educational status of the subjects, the
two areas did not differ. Current smokers were significantly
more frequent in the rural area than in the urban one. COPD
and COPDsx prevalences were significantly higher in Pisa,
while AO prevalence in the rural area.
Except for asthma, RD and AO resulted significantly
related to gender, smoking habit, and educational status,Table 2 General characteristics of studied subjects.
Mean (S.D.)
Po Delta (N ¼ 1946)
Age 39.5 (16.2)
FEV1% predicted
y 100.8 (14.3)
N (%)
Gender
Males 938 (48.2)
Females 1008 (51.8)
Education
Low 805 (41.4)
Intermediate 614 (31.6)
High 523 (26.9)
Missing 4 (0.2)
Smoking habit
Current 594 (30.5)
Ex 551 (28.3)
Never 801 (41.2)
RD
Asthma 107 (5.5)
COPD 58 (3.0)
COPDsx 392 (20.1)
AO 263 (15.1)
Current co-comorbidity
Cardio-vascular 458 (23.5)
Gastro-duodenal/liver 135 (6.9)
Kidney/colon 414 (21.3)
Joint 641 (32.9)
Dermatological 143 (7.3)
RD: respiratory symptoms/diseases; COPD: confirmed diagnosis of c
cough/phlegm. AO: airways obstruction according to the GOLD crite
Statistical difference between areas; NS: not significant.
y1746 and 1692 subjects with valid lung function tests in Po Delta
zIndependent comparison of the proportions between areas.regardless of residence. COPD, COPDsx, and AO resulted to
be more prevalent in males than in females, in current/ex
than in never smokers, and in less than in more educated
subjects (Table 3). NRD, especially joint and cardio-vascular,
were reported more by subjects with than without RD or AO
(Figure 1).Use of medicines
The subjects who reported habitual up-take of any drug
and specific medicines were 1164 (29.3%) and 567 (14.3%,
corresponding to 48.7% of the users), respectively (Table 4).
In the urban area of Pisa, there was a significantly larger
use of any or specific drugs than in the rural area of Po
Delta. Medicines were consumed more frequently by
women than men, by ex smokers than current smokers,
and by less educated than more educated subjects
(Table 4).p By Mann–Whitney
Pisa (N ¼ 2064)
45.0 (17.4) o0.001
98.0 (14.0) o0.001
N (%) p By w2
1000 (48.4) NS
1064 (51.7) NS
916 (44.4) NSz
567 (27.5) o0.01z
581 (28.1) NSz
–
547 (26.5) o0.001z
609 (29.5) NSz
908 (44.0) NSz
137 (6.6) NS
131 (6.3) o0.001
470 (22.8) o0.05
182 (10.8) o0.001
753 (37.5) o0.001
207 (10.0) o0.001
728 (35.3) o0.001
1012 (49.0) o0.001
178 (8.6) NS
hronic bronchitis and/or emphysema; COPDsx: COPD or chronic
rion (FEV1/FVC o70%).
and Pisa, respectively.
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Figure 1 Prevalence of non-respiratory diseases by respiratory symptoms/diseases (RD) and airway obstruction (AO).
Table 3 Prevalence (%) of respiratory symptoms/diseases (RD) and airway obstruction (AO) by gender, smoking habit, and
education.
Asthma COPD COPDsx AO
Prevalence (%) p Prevalence (%) p Prevalence (%) p Prevalence (%) p
Gender
Males 6.0 NS 7.0 o0.001 27.1 o0.001 17.1 o0.001
Females 6.1 2.6 16.2 8.8
Smoking habit
Current/Ex 6.2 NS 6.6 o0.001 28.0 o0.001 16.5 o0.001
Never 5.9 2.1 12.8 8.0
Education
Low 6.7 NS 7.5 o0.001 26.2 o0.001 19.9 o0.001
Intermediate 6.0 3.3 19.5 8.7
High 5.2 1.9 16.2 8.1
COPD: confirmed diagnosis of chronic bronchitis and/or emphysema; COPDsx: COPD or chronic cough/phlegm. AO: airways obstruction
according to the GOLD criterion (FEV1/FVC o70%).
M. Simoni et al.86In both areas, the prevalence of medicine up-take
increased with ageing (po0.001). The area of residence
did not significantly affect the relationship between drug
usage and age, gender, smoking habit or education.
Medicines of the cardio-vascular therapeutic group were
the most frequently used (41%). Broncho-pulmonary drugs,
diuretics, and anti-allergics were used by 5%, 7%, and 2% of
subjects, respectively (Table 5). Most frequently assumed
broncho-pulmonary medicines were metil-xantines, fol-
lowed by short-acting b2-agonists, inhaled corticosteroids,
and mucolitics (Figure 2).
Table 6 shows the prevalence of habitual drug use in
subjects with respiratory disorders. A sizeable proportion of
people with RD or AO did not report use of medicines. The
subjects with COPD showed the highest prevalence of drug
use (both any and specific). Except for people with COPD, a
larger up-take of medicines was evident in the urban than in
the rural area. The geographical difference in the use ofdrugs resulted statistically significant for subjects with
COPDsx and AO.
By logistic regression models, the use of medicines was
positively and significantly associated with all RDs and AO
(independent variables in separated models) after adjusting
for NRD (Figure 3, Model 1), and further for sex, age,
residential area, education, and smoking habit (Figure 3,
Model 2).
By subsequent logistic regression analyses, with RD
and AO in the same model, after accounting for all
confounding factors, asthma and COPD were associated
with any drug use (Table 7). Only asthma was significantly
related to the up-take of specific medicines. After stratifi-
cation for area, asthma and AO resulted, associated
with drug usage (both any and specific) in Pisa. In Po
Delta area, COPD was significantly related to the use of
any medicine and asthma to the use of specific drugs
(Table 7).
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Table 4 Proportions (%) of the habitual use of medi-
cines by gender, smoking habit, and educational status.
Total Po Delta Pisa p By w2
Any medicines
All 29.3 25.9 32.4 o0.001
Males 24.3 19.4 28.8 o0.001
Females 34.0 32.0 35.8 NS
py o0.001 o0.001 o0.001
Smoking habit
Current 26.2 23.4 29.3 o0.001
Ex 34.1 28.8 38.9 NS
Never 28.0 25.8 30.0 o0.05
py o0.001 NS o0.001
Education
Low 41.1 37.3 44.3 o0.01
Intermediate 21.0 16.9 25.4 o0.001
High 19.8 19.0 20.5 NS
py o0.001 o0.01 o0.001
Specific medicinesz
All 14.3 11.8 16.5 o0.001
Males 14.1 11.3 16.8 o0.001
Females 14.4 12.4 16.3 o0.01
py NS NS NS
Smoking habit
Current 10.2 8.5 12.1 o0.01
Ex 18.5 15.0 21.7 o0.05
Never 14.0 12.1 15.7 o0.05
py o0.001 o0.01 o0.001
Education
Low 24.0 21.5 26.1 o0.01
Intermediate 7.2 4.0 10.6 o0.001
High 6.7 6.2 7.2 NS
py o0.001 o0.001 o0.001
NS: not significant.
Between areas.
yBetween categories.
zAntiallergic or broncho-pulmonary or cardio-vascular or
diuretic medicines.
Table 5 Habitual use (%) of medicines by therapeutic
group.
Therapeutic group % of users
Cardio-vascular 40.5
Hormon-opotherapic 16.5
Neurologic 15.6
Gastroenteric 9.7
Dermatologic 9.1
Metabolic-antidiabetic 7.2
Diuretic 7.0
Articular-antiphlogistic 5.7
Broncho-pulmonary 5.2
Hematologic 4.7
Analgesic-antipyretic 3.3
Antiallergic 2.1
Specific medicines.
Respiratory health and medicine use in two Italian areas 87Discussion
Our results confirm the underuse of medicines in spite of
reported respiratory disorders. After accounting for all
confounding factors, asthma was the only condition sig-
nificantly associated with the use of specific drugs,
independently from the area of residence. In general, the
use of medicines resulted higher in the urban than in the
rural area.
The higher prevalence of COPD, COPDsx, and asthma in
the urban than in the rural area might be explained by the
significantly older age of the subjects living in Pisa.
However, the results did not change after stratification for
age groups. This ‘urban effect’ might be due to higher
pollution in the urban than in the rural environment, a
condition that occurred in our study areas, too.17–19 Otherauthors report larger presence of respiratory symptoms in
urban/industrial than in suburban/rural areas,27–29 and
several surveys have found relationships between respira-
tory health and environmental pollution.30–32
The prevalence rate of AO was higher in the rural than in
the urban area. This was probably due to the different
instruments used in the two surveys. In fact, according to
our experience,33–35 a pneumotachograph (like the one used
in Po Delta survey) systematically measures higher values of
FVC (not of FEV1) than a water-sealed spirometer (like the
one used in Pisa), thus yielding increased probabilities of AO
when a fixed percentage of the absolute ratio FEV1/FVC is
used as proposed by the GOLD criterion.25
The higher prevalence of any medicine consumption by
females than males was due to the use of antiphlogistics (2.1
vs 1.1, po0.01 by w2), diuretics (2.5 vs 1.6, p ¼ 0.05),
neurologics (5.7 vs 3.3, po0.001), and hormones (8.2 vs 1.1,
po0.001). The latter were likely assumed as contracep-
tives, as 77% of the women who assumed hormones were
below 50 year old.
The largest use of cardio-vascular medicines is consistent
with other reports36–39 and with the regional data of Veneto
and Tuscany, too.40
The higher prevalence of any drug use in ex- than in
current smokers, especially in the elderly, may be a clue for
a preferential smoking cessation in sick people.
The larger use of medicines in the urban area cannot be
explained by smoking habit, education, and sex since they
did not differ between the two areas. This ‘‘urban’’ effect
might be linked to the older age of the Pisa sample. Indeed,
after stratification by age groups, the difference between
the two areas was no more significant, as well as the
residential area did not enter significantly the logistic
multiple regression analysis, where age was a significant
determinant of medicine up-take. People aging in the urban
environment are likely exposed to higher pollution for a long
time. Indeed, Hajat et al.41 found an adverse effect of air
pollution on primary care consultations for upper respiratory
symptoms. It is also possible that in the urban area people
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15%
Figure 2 Broncho-pulmonary medicines. Frequency of use by
type (other ¼ systemic corticosteroids, balsamic or antiallergic
medicines).
Table 6 Proportions (%) of the habitual use of medicines in subjects with respiratory symptoms/diseases (RD) and airflow
obstruction (AO).
Any medicine Specific medicines
Total Po Delta Pisa py Total Po Delta Pisa py
RD
Asthma 41.7 36.2 46.0 NS 29.9 24.8 32.8 NS
COPD 58.7 60.3 58.0 NS 38.1 37.9 38.2 NS
COPDsx 38.4 32.8 43.0 o0.001 21.8 16.5 26.2 o0.001
AO 39.9 34.0 48.4 o0.001 24.7 18.9 33.0 o0.001
COPD: confirmed diagnosis of chronic bronchitis and/or emphysema; COPDsx: COPD or chronic cough/phlegm. AO: airways obstruction
according to the GOLD criterion (FEV1/FVC o70%).
Antiallergic or broncho-pulmonary or cardio-vascular or diuretic medicines.
yBetween areas (by w2); NS: not significant.
M. Simoni et al.88take better care of their own health, go more frequently to
the doctor’s office, and family practitioners more often tend
to prescribe medicines. Reduced prescription may occur for
professional isolation in rural locations, limited access to
other health services, or different patient’s demand related
to possible distance from the practitioner surgery.42
People with COPD exhibited the highest use of habitual
medicaments, but this was likely due to the higher
prevalence of comorbidity among the subjects with COPD,
especially of cardio-vascular diseases (56% vs 40% in subjects
with COPDsx or AO, and 35% in asthmatic subjects). Pistelli
et al.43 found that cardio-vascular diseases are the most
important determinant of prognosis of subjects affected by
COPD (especially in the elderly). There is little doubt that
the presence of NRD plays an important role in drug use
among the subjects with COPD. After accounting for NRD,the association between the medicine up-take and COPD
resulted considerably lower (OR 2.47 vs 3.74; Figure 3,
Model 1). The same, even if less evident, occurred for
COPDsx and AO. On the opposite, NRD did not seem to
influence the relation between asthma and drug up-take. It
is to point out that the prevalence of NRD did not differ
between asthmatic and non-asthmatic subjects (66% vs 65%
for the whole NRD, 35% vs 30% for cardio-vascular diseases).
Concomitant diagnosis of asthma and COPD or concomi-
tant presence of asthma/COPDsx or AO are common among
patients from the general population, especially in the
elderly. This was confirmed in our samples too. Diagnosis of
current asthma was present in about 24% of subjects with
COPD, 19% of asthmatics also had COPD, and 50% of subjects
with AO also reported RD. The confounding effect of the
inter-relations among the different respiratory outcomes on
drug usage became evident when RD and AO were consi-
dered in the same model of logistic regression (Table 7).
Only asthma and COPD resulted significantly related to the
use of any drug, and only asthma was related to the use of
specific medicines.
The underuse of drugs (mainly specific) was evident in
both areas, in agreement with other studies.6,8,9 It might be
explained by the difficulty in diagnosing a disease like COPD
in absence of a widespread utilization of spirometry or by
poor compliance with physician’s prescription. The high
number of subjects with AO who did not report respiratory
diseases (50%) might be a clue of the under-utilization of the
spirometer as a diagnostic tool in usual clinical practice
outside hospitals, as recently confirmed by other authors.7 It
is to point out that van den Boom et al., in the DIMCA study,
reported that the presence of a gradual reduced lung
function is an insufficient reason for patients to seek
medical help.44
Some people are afraid to assume medications, in so far
as they fear side effects or tend to believe that drugs are
dangerous and unnecessary.45 Norvegian investigators, by
analysing expired drug packages returned to pharmacies,
revealed that many medicines had not been used, although
having been prescribed by the physician and purchased by
the patient.3
When evaluating the results, one has to consider that
family practitioners might perceive chronic asthma as a
ARTICLE IN PRESS
Table 7 Odds ratios (95% CI) for habitual use of medicines.
Medicine Factors OR (95% CI)
Total Po Delta Pisa
Any RD (ref. no.)
Asthma 1.47 (1.01–2.12) 1.14 (0.63–2.07) 1.71 (1.05–2.80)
COPD 1.65 (1.08–2.53) 2.83 (1.35–5.94) 1.16 (0.68–1.99)
COPDsx 1.00 (0.79–1.27) 1.09 (0.77–1.54) 0.98 (0.71–1.36)
AO 1.19 (0.92–1.53) 0.90 (0.63–2.07) 1.60 (1.10–2.33)
Smoking habit (ref. Never)
Current 1.25 (0.99–1.57) 1.25 (0.90–1.75) 1.23 (0.89–1.70)
Ex 1.45 (1.16–1.81) 1.36 (0.97–1.58) 1.51 (1.12–2.05)
Age (decades) 1.43 (1.32–1.54) 1.49 (1.32–1.68) 1.39 (1.25–1.54)
Sex (ref. Males) 2.04 (1.67–2.48) 2.53 (1.89–3.38) 1.70 (1.29–2.22)
Comorbidity (ref. none)
Cardio-vascular 4.57 (3.53–5.90) 5.11 (3.58–7.28) 4.54 (3.08–6.69)
Gastro-duodenal/liver 3.28 (2.21–4.86) 2.79 (1.60–4.89) 4.01 (2.25–7.14)
Kidney/colon 1.66 (1.24–2.23) 1.93 (1.29–2.87) 1.50 (0.96–2.33)
Joint 1.24 (0.90–1.71) 0.96 (0.61–1.52) 1.57 (0.98–2.52)
Dermatological 0.98 (0.45–2.10) 0.42 (0.10–1.79) 2.02 (0.78–5.25)
Area (ref. Po Delta) 0.92 (0.77–1.09) – –
Education (ref. High)
Intermediate 0.97 (0.76–1.24) 0.87 (0.61–1.23) 1.11 (0.79–1.55)
Low 0.90 (0.71–1.15) 0.77 (0.53–1.11) 1.04 (0.75–1.45)
Specific RD (ref. no.)
Asthma 3.11 (1.94–4.97) 2.25 (1.00–5.05) 3.50 (1.93–6.34)
COPD 1.30 (0.78–2.16) 2.51 (0.98–6.42) 0.96 (0.52–1.80)
COPDsx 0.93 (0.68–1.30) 0.77 (0.44–1.34) 1.11 (0.73–1.70)
AO 1.22 (0.88–1.68) 0.78 (0.48–1.26) 1.84 (1.18–2.86)
Smoking habit (ref. Never)
Current 0.91 (0.64–1.31) (0.49–1.52) 0.91 (0.57–1.45)
Ex 1.19 (0.86–1.66) 1.07 (0.62–1.84) 1.27 (0.83–1.92)
Age (decades) 1.94 (1.72–2.20) 2.28 (1.87–2.79) 1.72 (1.47–2.01)
Sex (ref. Males) 0.96 (0.71–1.29) 0.88 (0.54–1.42) 1.01 (0.69–1.47)
Comorbidity (ref. none)
Cardio-vascular 9.40 (5.85–15.13) 14.58 (7.03–30.22) 6.75 (3.57–12.79)
Gastro-duodenal/liver 0.90 (0.37–2.21) 0.31 (0.04–2.55) 1.37 (0.48–3.89)
Kidney/colon 1.64 (0.89–3.01) 2.77 (1.12–6.83) 0.93 (0.40–2.18)
Joint 1.46 (0.79–2.72) 1.62 (0.61–4.26) 1.27 (0.56–2.89)
Dermatological 2.40 (0.68–8.49) 1.94 (0.23–16.33) 3.47 (0.71–16.91)
Area (ref. Po Delta) 0.87 (0.68–1.13) – –
Education (ref. High)
Intermediate 0.84 (0.55–1.27) 0.68 (0.33–1.40) 1.07 (0.63–1.79)
Low 1.11 (0.77–1.61) 1.03 (0.57–1.87) 1.27 (0.79–2.04)
COPD: confirmed diagnosis of chronic bronchitis/emphysema; COPDsx: COPD or chronic cough/phlegm; AO: airways obstruction
according to the GOLD criterion (FEV1/FVC o70%). All variables in the same model.
Antiallergic or broncho-pulmonary or cardio-vascular or diuretic medicines.
Respiratory health and medicine use in two Italian areas 89form of irreversible airflow obstruction, thus encompassing
it within the term COPD.46
A possible limitation in our assessment of the use of
medicines by subjects with different RD, might be that data
were collected before or immediately after the publication
of the GINA guidelines on asthma.47 However, also after
updating of GINA guidelines on asthma48 and GOLD guide-
lines on COPD,49 the level of asthma control has been
confirmed to fall short of the goals for long-term manage-
ment in international guidelines.7,44Conclusion
Our results indicate that most people of the general
population who report presence of respiratory symptoms/
diseases or impaired lung function do not use medicines.
The underuse of medicines seems to be lower in the
urban than in the rural area. There is no doubt
that comorbidity has to be considered for a better
assessment of medicine up-take by subjects with respiratory
disorders.
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Figure 3 Odds ratios for association between the use of medicines and respiratory disorders. COPD: confirmed diagnosis of chronic
bronchitis/emphysema; COPDsx: COPD or chronic cough/phlegm; AO: airways obstruction according to the GOLD criterion (FEV1/
FVCo70%). Model 1 ¼ accounted for non-respiratory disorders (NRD); Model 2 ¼ accounted for NRD, sex, age, smoking habit,
residential area, and education. (—) any medicine and (  ) specific medicines (antiallergic or broncho-pulmonary or cardio-vascular
or diuretic drugs).
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